An observational study in Barretts Esophagus With Dysplasia, sponsored by Institut Paoli-Calmettes. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-12-14.
Sponsored by Institut Paoli-Calmettes · Observational
Influence of histological concordance on the risk of recurrence:
the histological concordance being the comparison between the biopsies and the endoscopic resection piece and its concordant response rate.
Influence of histological concordance on the risk of recurrence:
the histological concordance being the comparison between the biopsies and the endoscopic resection piece and its concordant response rate.
310 studies on the registry are indexed under Barrett Esophagus; 64 are open to participants now.
This study's enrollment of 18 is below the median of 127 across 115 observational studies indexed under Barrett Esophagus.
Browse Barrett Esophagus studies →Institut Paoli-Calmettes is the lead sponsor of 168 studies on the registry; 50 are open to participants now.
Counted across the registry records on this site, refreshed daily.
patients with DHG on Barrett's esophagus on endoscopic biopsies followed by endoscopic resection.
Exclusion Criteria:
-
patients with DHG on Barrett's esophagus on endoscopic biopsies followed by endoscopic resection
Diagnostic Test: Pathological revision
Pathological revision
Influence of histological concordance on the risk of recurrence
the histological concordance being the comparison between the biopsies and the endoscopic resection piece and its concordant response rate.
Time frame: 1 day
Identification of histological factors of recurrence.
Identification of histological factors of recurrence.
Time frame: 1 day
Plan to share: No
This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Institut Paoli-Calmettes